公开(公告)号：US06723498B1

公开(公告)日：2004-04-20

申请号：US09340264

申请日：1999-06-30

申请人： Andrew W. Shyjan ,  Mark Williamson ,  Shengfang Jin

发明人： Andrew W. Shyjan ,  Mark Williamson ,  Shengfang Jin

IPC分类号： C12Q100

CPC分类号： C12Q1/6809 ,  C12Q1/6886 ,  G01N33/5011 ,  G01N33/573 ,  G01N2333/9108 ,  G01N2333/9121

摘要： Increased expression of Chk1 is associated with drug resistance of certain cells (e.g., cancer cells). The invention provides methods for identifying drug resistant cells by measuring the expression or activity of Chk1, methods for identifying modulators of drug resistance, and methods for modulating drug resistance by modulating the expression or activity of Chk1.

摘要翻译： Chk1的增加的表达与某些细胞（例如癌细胞）的耐药性相关。 本发明提供了通过测量Chk1的表达或活性，鉴定药物抗性调节剂的方法和通过调节Chk1的表达或活性来调节药物抗性的方法来鉴定耐药性细胞的方法。

公开(公告)号：US06423494B1

公开(公告)日：2002-07-23

申请号：US09470175

申请日：1999-12-22

申请人： Shengfang Jin ,  Andrew W. Shyjan ,  Christophe Van Huffel

发明人： Shengfang Jin ,  Andrew W. Shyjan ,  Christophe Van Huffel

IPC分类号： C12Q168

CPC分类号： G01N33/57419 ,  G01N33/5011

摘要： Increased expression of DR6 is associated with drug resistance of certain cells (e.g., cancer cells). The invention provides methods for identifying drug resistant cells by measuring the expression or activity of DR6, methods for identifying modulators of drug resistance, and methods for modulating drug resistance by modulating the expression or activity of DR6.

摘要翻译： DR6的增加的表达与某些细胞（例如癌细胞）的耐药性相关。 本发明提供了通过测量DR6的表达或活性，鉴定药物抗性调节剂的方法以及通过调节DR6的表达或活性来调节耐药性的方法来鉴定耐药性细胞的方法。

公开(公告)号：US06312909B1

公开(公告)日：2001-11-06

申请号：US09534242

申请日：2000-03-23

申请人： Andrew W. Shyjan

发明人： Andrew W. Shyjan

IPC分类号： C12Q168

CPC分类号： C07K14/82 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/00 ,  C12N15/1034

摘要： The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumor progression in cells involved in human tumors such as melanomas, breast, gastrointestinal, lung, and bone tumors, various types of skin cancers, and other neoplastic conditions such as leukemias and lymphomas. Genes are identified that are differentially expressed in benign (e.g., non-malignant) tumor cells relative to malignant tumor cells exhibiting a high metastatic potential. Genes are also identified via the ability of their gene products to interact with gene products involved in the progression to, and/or aggressiveness of, neoplastic tumor disease states. The genes and gene products identified can be used diagnostically or for therapeutic intervention.

摘要翻译： 本发明涉及用于诊断，预防和治疗涉及人肿瘤的细胞如黑素瘤，乳腺癌，胃肠道，肺癌和骨肿瘤，各种类型的皮肤癌和其它肿瘤病症中的肿瘤进展的方法和组合物 作为白血病和淋巴瘤。 鉴定出相对于表现出高转移潜能的恶性肿瘤细胞，在良性（例如，非恶性）肿瘤细胞中差异表达的基因。 基因也通过其基因产物与涉及肿瘤肿瘤疾病状态进展和/或侵袭性的基因产物相互作用的能力来鉴定。 鉴定的基因和基因产物可用于诊断或治疗干预。

公开(公告)号：US6100031A

公开(公告)日：2000-08-08

申请号：US35648

申请日：1998-03-05

申请人： Andrew W. Shyjan

发明人： Andrew W. Shyjan

IPC分类号： A61K38/00 ,  C07K14/47 ,  C07K14/82 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C07K14/4703 ,  C07K14/82 ,  A61K38/00 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers (e.g., colon cancer) in mammals, e.g., humans. The invention is based on the discovery of genes that are differentially expressed in tumor cells relative to normal cells. The genes identified can be used diagnostically or as targets for therapy, and can be used to identify compounds useful in the diagnosis, prevention, and therapy of tumors and cancers.

摘要翻译： 本发明涉及用于诊断，预防和治疗哺乳动物（例如人）中的肿瘤和癌症（例如结肠癌）的方法和组合物。 本发明基于相对于正常细胞在肿瘤细胞中差异表达的基因的发现。 所鉴定的基因可用于诊断或作为治疗的靶标，并且可用于鉴定可用于诊断，预防和治疗肿瘤和癌症的化合物。

公开(公告)号：US5837837A

公开(公告)日：1998-11-17

申请号：US807200

申请日：1997-02-27

申请人： John J. Hunter ,  Andrew W. Shyjan ,  Grace H. W. Wong

发明人： John J. Hunter ,  Andrew W. Shyjan ,  Grace H. W. Wong

IPC分类号： A61K38/00 ,  A61K48/00 ,  C12N9/64 ,  C07H21/02 ,  C07K1/00

CPC分类号： C12N9/6475 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00

摘要： The present invention concerns the Caspase-8h gene and the Caspase-8i gene. The Caspase-8h gene encodes a 220 amino acid polypeptide having two FADD death effector domains. The Caspase-8i gene encodes an 81 amino acid polypeptide having one FADD death effector domain. The invention encompasses nucleic acid molecules encoding Caspase-8h or Caspase-8i, vectors containing these nucleic acid molecules, and cells harboring such vectors.

摘要翻译： 本发明涉及Caspase-8h基因和Caspase-8i基因。 Caspase-8h基因编码具有两个FADD死亡效应子结构域的220个氨基酸的多肽。 Caspase-8i基因编码具有一个FADD死亡效应子结构域的81个氨基酸多肽。 本发明包括编码Caspase-8h或Caspase-8i的核酸分子，含有这些核酸分子的载体和含有这些载体的细胞。

公开(公告)号：US20110314565A1

公开(公告)日：2011-12-22

申请号：US13104316

申请日：2011-05-10

申请人： Nathaniel Heintz ,  Tito A. Serafini ,  Andrew W. Shyjan

发明人： Nathaniel Heintz ,  Tito A. Serafini ,  Andrew W. Shyjan

IPC分类号： A01K67/027 ,  C12N1/19 ,  C07K14/00 ,  A01K67/033 ,  A01H5/00 ,  C07K19/00 ,  C07H1/08 ,  C12N5/10

CPC分类号： C12N15/1041 ,  C12N15/1006 ,  C12N15/82 ,  C12N15/8222 ,  C12Q1/6827

摘要： The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA hound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or protein that binds mRNA fused to a nucleotide sequence encoding a peptide tag. The tagged ribosome or mRNA binding protein can then be isolated, along with the mRNA bound to the tagged ribosome or mRNA binding protein, and the mRNA isolated and further used for gene expression analysis. The methods of the invention facilitate the analysis and quantification of gene expression in the selected cell type present within a heterogeneous cell mixture, without the need to isolate the cells of that cell type as a preliminary step.

摘要翻译： 本发明提供了通过选择性分离以细胞类型特异性方式结合mRNA的核糖体或蛋白质分离细胞型特异性mRNA的方法，从而将mRNA捕获到结合mRNA的核糖体或蛋白质上。 作为核糖体复合物的核糖体结合正在细胞中积极翻译的mRNA。 根据本发明的方法，将细胞工程化以表达分子标记的核糖体蛋白质或蛋白质，其通过向细胞中引入核酸，所述核酸包含编码核糖体蛋白质或蛋白质的核苷酸序列，所述核糖体蛋白质或蛋白质与编码 肽标签。 然后可以分离标记的核糖体或mRNA结合蛋白以及与标记的核糖体或mRNA结合蛋白结合的mRNA，并分离mRNA并进一步用于基因表达分析。 本发明的方法促进了在异质细胞混合物中存在的所选细胞类型中的基因表达的分析和定量，而不需要将该细胞类型的细胞作为初步步骤分离。

公开(公告)号：US06872811B1

公开(公告)日：2005-03-29

申请号：US09163759

申请日：1998-09-30

申请人： Kyle J. MacBeth ,  Andrew W. Shyjan

发明人： Kyle J. MacBeth ,  Andrew W. Shyjan

IPC分类号： G01N33/53 ,  A61K38/00 ,  C07K14/47 ,  C07K14/82 ,  C07K16/32 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12Q1/02 ,  C12Q1/68 ,  C12N15/11 ,  C12N1/20 ,  C12N15/00

CPC分类号： C07K14/4748 ,  A61K38/00 ,  C12Q1/6809 ,  C12Q1/6886 ,  C12Q2600/136

摘要： The invention concerns cDNA molecules encoding HRPCa 9 and HRPCa 10 both of which are constitutively expressed in the androgen-independent cell line, LN3 LNAcP and induced by testosterone in the androgen-dependent cell line, LNAcP.The invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention. The invention also provides screening assays which can be used to identify compounds useful for the treatment of prostate cancer (e.g., androgen-independent prostate cancer).

摘要翻译： 本发明涉及编码HRPC9和HRPCa10的cDNA分子，它们都在雄激素依赖性细胞系LN3 LNAcP中组成型表达，并且在雄激素依赖性细胞系LNAcP中由睾丸激素诱导。本发明提供了分离的核酸分子，其编码 本发明的多肽或其生物活性部分。 本发明还提供了适用于检测编码本发明多肽的核酸的引物或杂交探针的核酸分子。 本发明还提供可用于鉴定可用于治疗前列腺癌的化合物（例如，雄激素依赖性前列腺癌）的筛选试验。

公开(公告)号：US06268470B1

公开(公告)日：2001-07-31

申请号：US09001951

申请日：1997-12-31

申请人： Andrew W. Shyjan

发明人： Andrew W. Shyjan

IPC分类号： A61K3800

CPC分类号： C12Q1/6886 ,  A61K38/00 ,  C07K14/4703 ,  C07K14/82 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers (e.g., colon cancer) in mammals, e.g., humans. The invention is based on the discovery of genes that are differentially expressed in tumor cells relative to normal cells. The genes identified can be used diagnostically or as targets for therapy, and can be used to identify compounds useful in the diagnosis, prevention, and therapy of tumors and cancers.

摘要翻译： 本发明涉及用于诊断，预防和治疗哺乳动物（例如人）中的肿瘤和癌症（例如结肠癌）的方法和组合物。 本发明基于相对于正常细胞在肿瘤细胞中差异表达的基因的发现。 所鉴定的基因可用于诊断或作为治疗的靶标，并且可用于鉴定可用于诊断，预防和治疗肿瘤和癌症的化合物。

公开(公告)号：US06251597B1

公开(公告)日：2001-06-26

申请号：US09181030

申请日：1998-10-27

申请人： Andrew W. Shyjan

发明人： Andrew W. Shyjan

IPC分类号： C12Q168

CPC分类号： C12N15/1034 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/00 ,  C07K14/82

摘要： The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumor progression in cells involved in human tumors such as melanomas, breast, gastrointestinal, lung, and bone tumors, various types of skin cancers, and other neoplastic conditions such as leukemias and lymphomas. Genes are identified that are differentially expressed in benign (e.g., non-malignant) tumor cells relative to malignant tumor cells exhibiting a high metastatic potential. Genes are also identified via the ability of their gene products to interact with gene products involved in the progression to, and/or aggressiveness of, neoplastic tumor disease states. The genes and gene products identified can be used diagnostically or for therapeutic intervention.

摘要翻译： 本发明涉及用于诊断，预防和治疗涉及人肿瘤的细胞如黑素瘤，乳腺癌，胃肠道，肺癌和骨肿瘤，各种类型的皮肤癌和其它肿瘤病症中的肿瘤进展的方法和组合物 作为白血病和淋巴瘤。 鉴定出相对于表现出高转移潜能的恶性肿瘤细胞，在良性（例如，非恶性）肿瘤细胞中差异表达的基因。 基因也通过其基因产物与涉及肿瘤肿瘤疾病状态进展和/或侵袭性的基因产物相互作用的能力来鉴定。 鉴定的基因和基因产物可用于诊断或治疗干预。

公开(公告)号：US06172190B2

公开(公告)日：2001-01-09

申请号：US09001777

申请日：1997-12-31

申请人： John J. Hunter ,  Andrew W. Shyjan ,  Grace H. W. Wong

发明人： John J. Hunter ,  Andrew W. Shyjan ,  Grace H. W. Wong

IPC分类号： C07K100

CPC分类号： C12N9/6475 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00

摘要： The present invention relates to the discovery and characterization of two novel forms of Caspase-8. The first Caspase-8 of the invention, Caspase-8h, encodes a 220 amino acid polypeptide which includes two FADD death effector domains. The second caspase of the invention, Caspase-8i, encodes an 81 amino acid polypeptide having one FADD death effector domain. The invention encompasses nucleic acid molecules encoding Caspase-8h and Caspase-8i, vectors containing these nucleic acid molecules, cells harboring recombinant DNA encoding Caspase-8h and/or Caspase-8i, host fusion proteins which include Caspase-8h and/or Caspase-8i, transgenic animals which express Caspase-8h and/or Caspase-8i, therapeutic methods, purified Casapase-8h, purified Casapase-8i, therapeutic compounds and methods employing Caspase-8h and Caspase-8i, and screening methods employing Caspase-8h and Caspase-8i.

摘要翻译： 本发明涉及两种新型胱天蛋白酶-8的发现和表征。 本发明的第一种Caspase-8，Caspase-8h编码220个氨基酸的多肽，其包括两个FADD死亡效应子结构域。 本发明的第二胱天蛋白酶Caspase-8i编码具有一个FADD死亡效应子结构域的81个氨基酸多肽。本发明包括编码半胱天冬酶-8h和半胱天冬酶-8i的核酸分子，含有这些核酸分子的载体，含有重组DNA的细胞 编码Caspase-8h和/或Caspase-8i的宿主融合蛋白包括Caspase-8h和/或Caspase-8i，表达Caspase-8h和/或Caspase-8i的转基因动物，治疗方法，纯化的Casapase-8h，纯化的Casapase -8i，使用半胱天冬酶-8h和胱天蛋白酶-8i的治疗化合物和方法，以及采用半胱天冬酶-8h和半胱天冬酶-8i的筛选方法。